USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
22 Mar 2022 | 03:45 PM GMT

Masterclass: Reimbursement of DTx in the US - Demystifying US Payer Access Negotiations

Anchored by:

Mike Pace
Founder & CEO
PALMHEALTHCO
Stephen Dunne
Chief Product & Technology Officer - Managing
KOA HEALTH

Participants:

Mike Pace Founder & CEOPalmHealthCo
Mike Pace
Founder & CEOPalmHealthCo
Stephen Dunne Chief Product & Technology Officer - ManagingKoa Health
Stephen Dunne
Chief Product & Technology Officer - ManagingKoa Health
Brendan Staunton CEOAmara Therapeutics
Brendan Staunton
CEOAmara Therapeutics
Christopher Hall Commercial Director, APACMarula Health
Christopher Hall
Commercial Director, APACMarula Health
Dorothy Hoffman Exec Dir, Head of Global ImmunologNovartis
Dorothy Hoffman
Exec Dir, Head of Global ImmunologNovartis
Grace McNamara CEOEXi
Grace McNamara
CEOEXi
Hassan Naqvi Lead Digital Health CommercializationAstraZeneca
Hassan Naqvi
Lead Digital Health CommercializationAstraZeneca
Jared Augenstein Senior Managing DirectorManatt Health
Jared Augenstein
Senior Managing DirectorManatt Health
Joseph Koziak Chief Executive OfficerRevibe Technologies
Joseph Koziak
Chief Executive OfficerRevibe Technologies
Mithun Ratnakumar Director Technology Strategy & GovernanceGerresheimer
Mithun Ratnakumar
Director Technology Strategy & GovernanceGerresheimer
Uma Makhija Verma Senior Director Business DevelopmentBiogen
Uma Makhija Verma
Senior Director Business DevelopmentBiogen

About this Meeting

Are you a DTx or Pharma company seeking Payer Reimbursement of a DTx product in the US? Keep reading, this masterclass is for you. 

Even though generating evidence, demonstrating value, building stakeholder advocacy & product demand, and achieving desired regulatory status are important steps in the DTx commercialization journey, establishing coverage and reimbursement by public and private payers will be crucial for higher DTx revenue potential. In this masterclass led by Mike Pace we will focus on: 

  • How to approach payers and be seen as a trusted advisor: understanding archetypes, their business drivers, motivations and needs 
  • What type of access negotiation and contracts are best suited for the different types of payers in the market: Commercial Health Plans, PBMs, Medicaid, Employers? How does the strategy change between Prescription DTx (PDT) and non-PDT?
  •  Recent news on payers not covering PDTs (e.g. Aetna and BCBS plan policies) - What are the challenges arising from this news? How does it inform DTx access negotiations? 
  •  Real examples: best practices, learnings and contracting expectations.